Skip to main content
. 2018 Jul 27;10(8):982. doi: 10.3390/nu10080982

Figure 3.

Figure 3

Venn diagram of differentially expressed genes in mice treated with rifampicin, menaquinone-4, and control mice. (A–C) Genes that were (A) upregulated (more than twice), (B) downregulated (to below 0.5-fold), or (C) overall differentially expressed after the treatment with rifampicin (Rif) or menaquinone-4 (MK-4) in comparison with the levels in control (Cont) hPXR mice. Overall, there were 29 shared differentially expressed genes between Rif- and MK-4 treated groups (eight upregulated and 21 downregulated). Five hundred and two genes (135 upregulated and 367 downregulated) and 590 genes (299 upregulated and 291 downregulated) differentially expressed genes were unique for Rif- and MK-4 treated hPXR mice, respectively. (D–F) Genes that were (D) upregulated (more than twice), (E) downregulated (to below 0.5-fold), or (F) overall differentially expressed in comparison with the levels in control (Cont) WT and hPXR mice. Overall, there were 26 shared differentially expressed genes between MK-4 treated hPXR and WT groups (nine upregulated and 17 downregulated). Five hundred and ninety-three (298 upregulated and 295 downregulated) and 437 (257 upregulated and 180 downregulated) differentially expressed genes were unique for MK-4 treated hPXR and WT mice, respectively.